After taking part in this activity, participants will be able to:

• Evaluate the significance of clot pathology and structure in patients with haemophilia with inhibitors and assess its impact on treatment choices and dosing

• Identify the goals and need for prophylaxis for patients with severe haemophilia and haemophilia with inhibitors

• Assess current and emerging treatment options for patients with haemophilia with inhibitors and review the clinical evidence that supports their use

• Apply knowledge of the mode of action of by-passing agents to develop strategies for the care and management of patients with haemophilia with inhibitors